SCHEMBL26120048

SCHEMBL26120048

CC(C)(C)OC(=O)N1CCC(Nc2nccc(-c3ccn4nccc4n3)n2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.47
IDH1 O75874 1/20 0.46
IDH2 P48735 1/20 0.46
ALDH1A1 P00352 2/20 0.45
MAPK9 P45984 6/20 0.45
MAPK8 P45983 5/20 0.45
CDK2 P24941 4/20 0.45
JUN P05412 4/20 0.45
MAPK10 P53779 3/20 0.45
MAPK1 P28482 3/20 0.45
NPC1 O15118 1/20 0.45
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CCNA2 P20248 1/20 0.44
SYK P43405 1/20 0.43
GPR119 Q8TDV5 3/20 0.42
DGAT1 O75907 1/20 0.42
USP30 Q70CQ3 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30603249 1.00 ADORA2A (0.47) ADORA2AIDH1IDH2ALDH1A1MAPK9
SCHEMBL26506937 0.86 GRIN2B (0.47) GPR119
SCHEMBL26507050 0.83 PCSK9 (0.42) MAPK9MAPK8CDK2MAPK10MAPK1
SCHEMBL26507191 0.83 PCSK9 (0.42) MAPK9MAPK8CDK2MAPK10MAPK1
SCHEMBL26114178 0.82 PCSK9 (0.41) GPR119USP30
SCHEMBL14190733 0.79 ALDH1A1 (0.55) ADORA2AIDH1IDH2ALDH1A1CDK2
SCHEMBL12367077 0.79 ALDH1A1 (0.55) ADORA2AIDH1IDH2ALDH1A1CDK2
SCHEMBL3650816 0.79 HDAC8 (0.52) ADORA2AIDH1IDH2ALDH1A1MAPK9
SCHEMBL26505551 0.78 CDK1 (0.48) MAPK9MAPK8CDK2MAPK10CCNA2
SCHEMBL4062890 0.78 GPR119 (0.61) ADORA2AIDH1IDH2ALDH1A1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049086-A1 CDK9 INHIBITORS BAERENKRAFT THERAPEUTICS LLC (US) 2026-02-19 US disclosed
US-12275738-B2 CDK9 inhibitors Biolexis Therapeutics, Inc. (US) 2025-04-15 US disclosed
WO-2023196517-A1 CDK9 INHIBITORS Biolexis Therapeutics, Inc. (US) 2023-10-12 WO disclosed
WO-2023196517-A1 CDK9 INHIBITORS Biolexis Therapeutics, Inc. (US) 2023-10-12 WO disclosed
US-20230322792-A1 CDK9 INHIBITORS BAERENKRAFT THERAPEUTICS, LLC 2023-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322792-A1 CDK9 INHIBITORS CDK9, CDK19, CDK3 ADORA2A 3437/4885IDH1 1470/4885IDH2 2305/4885
US-20260049086-A1 CDK9 INHIBITORS CDK9, CDK6, CDK19 ADORA2A 3800/4885IDH1 1033/4885IDH2 1915/4885
US-12275738-B2 CDK9 inhibitors CDK9, CDK19, CDK3 ADORA2A 3437/4885IDH1 1470/4885IDH2 2305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.